These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1082 related articles for article (PubMed ID: 16413397)
1. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation. Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397 [TBL] [Abstract][Full Text] [Related]
2. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Devine SM; Brown RA; Mathews V; Trinkaus K; Khoury H; Adkins D; Vij R; Sempek D; Graubert T; Tomasson M; Goodnough LT; DiPersio JF Bone Marrow Transplant; 2005 Sep; 36(6):531-8. PubMed ID: 16025152 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931 [TBL] [Abstract][Full Text] [Related]
4. Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Dhédin N; Prébet T; De Latour RP; Katsahian S; Kuentz M; Piard N; Réa D; Norol F; Jouet JP; Ribeil JA; Tabrizi R; Rio B; Lioure B; Tiberghien P; Bourhis JH; Sirvent A; Bordigoni P; Blaise D; Michallet M; Vernant JP Bone Marrow Transplant; 2012 Dec; 47(12):1564-8. PubMed ID: 22609881 [TBL] [Abstract][Full Text] [Related]
5. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124 [TBL] [Abstract][Full Text] [Related]
6. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Remberger M; Naseh N; Aschan J; Barkholt L; LeBlanc K; Svennberg P; Ringdén O Bone Marrow Transplant; 2003 Jul; 32(2):217-23. PubMed ID: 12838288 [TBL] [Abstract][Full Text] [Related]
7. The helper T lymphocyte precursor (HTLp) frequency does not predict outcome after HLA-identical sibling donor G-CSF-mobilised peripheral blood stem cell transplantation. Healey G; Schwarer AP Bone Marrow Transplant; 2002 Sep; 30(6):341-6. PubMed ID: 12235517 [TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
9. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases]. Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932 [TBL] [Abstract][Full Text] [Related]
10. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies. Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507 [TBL] [Abstract][Full Text] [Related]
11. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Yamasaki S; Henzan H; Ohno Y; Yamanaka T; Iino T; Itou Y; Kuroiwa M; Maeda M; Kawano N; Kinukawa N; Miyamoto T; Nagafuji K; Shimoda K; Inaba S; Hayashi S; Taniguchi S; Shibuya T; Gondo H; Otsuka T; Harada M; Bone Marrow Transplant; 2003 Sep; 32(5):505-10. PubMed ID: 12942097 [TBL] [Abstract][Full Text] [Related]
12. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model. Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478 [TBL] [Abstract][Full Text] [Related]
13. [Collection of hematopoietic progenitor cells from healthy donors]. Bojanić I; Cepulić BG; Mazić S Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352 [TBL] [Abstract][Full Text] [Related]
14. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248 [TBL] [Abstract][Full Text] [Related]
15. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Iori AP; Torelli GF; De Propris MS; Milano F; Pupella S; Gozzer M; Mancini F; Milani ML; Intoppa S; Cerretti R; Lucarelli B; Valle V; Malandruccolo L; Iannella E; Arleo E; Guarini A; Foà R Transplantation; 2008 Feb; 85(3):386-90. PubMed ID: 18322430 [TBL] [Abstract][Full Text] [Related]
16. Low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells. Ji S; Chen H; Wang H; Ma J; Pan S; Xue M; Zhu L; Liu J; Xiao M; Zhou L Chin Med J (Engl); 2001 Feb; 114(2):191-5. PubMed ID: 11780205 [TBL] [Abstract][Full Text] [Related]
17. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046 [TBL] [Abstract][Full Text] [Related]
18. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection. Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543 [TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. Urbano-Ispizua A; Solano C; Brunet S; de la Rubia J; Odriozola J; Zuazu J; Figuera A; Caballero D; Martínez C; García J; Sanz G; Torrabadella M; Alegre A; Pérez-Oteiza J; Jurado M; Oyonarte S; Sierra J; García-Conde J; Rozman C Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]